Psilocybin in Co-occuring Major Depressive Disorder and Borderline Personality Disorder

• Status: Not yet recruiting
• Trial end date: 2023-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The primary objective of the study is to evaluate the safety and efficacy of psilocybin in adults with major depressive disorder (MDD) and borderline personality disorder (BPD).

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Chicago
• Collaborator: Usona Institute
• Treatments: Psilocybin

Criteria

Inclusion Criteria:

• Age 18-65

• Diagnosed with current major depressive disorder

• Montgomery-Asberg Depression Rating Scale (MADRS) score of > 20

• Diagnosed with borderline personality disorder

• Zanarini Rating Scale for Borderline Personality Disorder (ZAN-BPD) score of > 9

• Ability to understand and sign the consent form

Exclusion Criteria:

• Unstable medical illness based on history or clinically significant abnormalities on baseline physical examination

• Current pregnancy or lactation, or inadequate contraception in women of childbearing potential

• Illegal substance use based on urine toxicology screening (except cannabis use)

• Current or past history of bipolar I disorder, schizophrenia, or schizoaffective disorder

• Active substance use disorder